They target a key cause of dry eye.
(Press Release) SANTA ANA, CA — TearScience, part of Johnson & Johnson Vision, announced at the American Academy of Ophthalmology 2017 Meeting that its LipiScan and LipiFlow technologies are now available in more than 800 optometrist and ophthalmologist offices in the U.S. and Canada.
Dry eye affects more than 340 million people around the world. Meibomian gland dysfunction is a leading cause of dry eye, found in an estimated 86 percent of dry eye patients. The LipiFlow System is a medical device treatment for MGD shown to improve mean gland function and dry eye symptoms. The efficacy of LipiFlow is supported by 30 peer-reviewed reports. LipiScan is a dedicated rapid high definition gland imager.
“We’re proud to announce this milestone — it’s a significant measure of our commitment to effectively treat this leading cause of dry eye,” said Joe Boorady, president and CEO, TearScience. “In joining forces with Johnson & Johnson Vision, we’ll connect more with the optometry and ophthalmology communities to assure they have the tools needed to optimize ocular surface health for millions of patients.”
“A healthy ocular surface is important for contact lenses or for cataract procedures,” said Tom Frinzi, worldwide president, surgical vision, Johnson & Johnson Vision. “TearScience technology is proven to treat one of the leading causes of dry eye, which is directly aligned with our product portfolio and our commitment to improve and restore sight for patients.”
Advertisement
For additional information on how TearScience improves meibomian gland function and symptoms for patients with MGD worldwide, visit www.TearScience.com.
